Search

Keep up to date with the latest news, innovations, and developments, spotlighting groundbreaking research and emerging players.

Stay informed on the latest financial trends and investment opportunities, from startups to established players.

Explore the intersection of psychedelic medicine and cultural values, diving into ethical considerations and societal impacts within this transformative field.

Navigate the complex legal and political landscape surrounding psychedelic medicine, including regulatory updates, policy changes, and advocacy efforts.

Delve into cutting-edge scientific research and breakthroughs in the field of psychedelic medicine, with a focus on understanding the mechanisms, efficacy, and safety of these substances.

Discover the therapeutic potential of psychedelic substances, examining their role in mental health, personal growth, and overall well-being.

Nov 9-11, 2023 | Miami, FL

The Premier Global Event for Psychedelics, Mental Health & Longevity

Delve into the captivating world of psychedelic medicine at Wonderland, where the frontiers of science, spirituality, and wellness converge to create an experience unlike any other.

Discover the keys to living longer while exploring the potential of humanity’s future. Wonderland brings together the latest groundbreaking research, charting trends, and investment opportunities for an experience of a lifetime.

Uncover state-of-the-art technology, evolving trends, insightful marketing strategies, and valuable opportunities designed for professionals in the mental health and brain care sector.

With this year’s Wonderland, we want to expand the conversation to take a deep dive into the intersection of these fields with psychedelic medicine, and how combining all three can lead to living not only a longer, but happier life.

The premier global conference, Wonderland is a groundbreaking event experience where visionaries and pioneers unite to explore the future of psychedelic medicine, the business of mental health and the future of longevity medicine.

Are you ready to share your passion, knowledge, and insights with a global audience of executives, researchers, and practitioners? This is your opportunity to contribute to the evolving conversation on the future of medicine showcase your unique expertise, and inspire change in the world.

Wonderland presents a one-of-a-kind opportunity for businesses and organizations to exhibit their cutting-edge products, services, and visionary solutions to a captivated audience of professionals in the mental health and psychedelic medicine fields.

We invite companies with a shared vision to submit partnership proposals and collaborate with us on this extraordinary event. By joining forces, we can create a truly unique experience for attendees, foster lasting connections, and drive the future of psychedelic healing together.

Elevate your brand’s presence in the psychedelic medicine industry with our comprehensive suite of services, tailored to captivate your audience, strengthen your market position, and foster meaningful connections within the community.

Our website provides a platform for a range of custom content, putting your message in front of the industry’s most engaged and informed audience.

Our advertising options give you the ability to target users on their desktops, mobile devices, or when they’re at one of our in-person events. You decide when and where to connect with our audience.

Our dedicated team provides passion and specialist insight across a variety of sectors and services so, whatever the challenge, the impact is guaranteed.

You’re doing the hard work of changing the world, let our team of internationally award-winning creators focus on spreading the word as far as possible and telling your story to the world.

Microdose’s events and conferences are bringing psychedelic medicine to the mainstream. Top investors, business leaders, researchers, and advocates — our events are the hub for the psychedelic renaissance.

Justin Hanka
MindBio Therapeutics

The team at Microdose are leaders in public relations activities and have successfully assisted MindBio Therapeutics to reach a global audience that we would not have been able to reach without them.

Natalie Dolphin
Wellbeing Digital Science

The Microdose team worked with us, identifying key activities we were undertaking and promoting them through its wide-ranging media connections within psychedelics, cannabis and biotech publications. The Microdose team is professional and passionate about what it does, and this was reinforced during the pandemic when it went above and beyond our agreed contract, working with us to get key messages out to the industry quickly and effectively.

Microdose X is shifting the world’s perception of psychedelic medicine, one city at a time. Join the world’s fastest-growing psychedelic network and enjoy vibrant local meetups with like-minded souls.

The Science of Psychedelics is an accredited, definitive guide to the clinical applications of entheogenic medicines, and offers a solid introduction to psychedelic-assisted therapy and “trip sitting” skills to physicians, psychologists, social workers, mental health counselors, pharmacists, and other empowered individuals. Become trained in psychedelic medicines like psilocybin, LSD, MDMA, and ketamine today.

Psychedelia is a quarterly publication examining the ever-changing realm of drug policy and efforts to bring psychedelic therapies into the mainstream. From psilocybin mushrooms to LSD to DMT, psychedelics have the potential to revolutionize mental healthcare in North America. Psychedelia will detail the journey towards acceptance of psychedelic-assisted therapies.

Microdose is a small team of people who want to help share the potential of psychedelic medicine with the world, bringing together our unique expertise and diverse backgrounds to create a platform that inspires, informs, and fosters a thriving community in this transformative field.

Our team shares a passion for psychedelic medicine and we all have a different story on how we ended up here. We want to share those stories and highlight the amazing people that help us do what we do.

Connect with our team to explore how we can collaborate and unlock the potential of psychedelic medicine together, fostering growth and innovation in this dynamic industry.

Field Trip Health Ltd. Common Shares to Trade on the OTCQX Best Market

TORONTO, Jan. 28, 2021 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) (“Field Trip“), a leader in the development and delivery of psychedelic therapies, is pleased to announce its common shares have been approved for trading on the OTCQX® Best Market (“OTCQX”) retaining its current symbol FTRPF, effective as of the opening of trading today, January 28, 2021. Field Trip’s shares and warrants continue to trade on the Canadian Securities Exchange under the tickers FTRP and FTRP.WT, respectively.

“Our quotation on the OTCQX Best Market from the Pink® market marks an important step for Field Trip in bringing our integrated psychedelics business to a wider range of U.S. and international institutional and retail investors,” said Ronan Levy, Field Trip’s Executive Chairman. “The OTCQX is the top tier of OTC Markets, with the most stringent entry requirements, and we expect this move will help improve liquidity and broaden our investor base. Our Field Trip Discovery and Field Trip Health divisions are at the forefront of the psychedelics industry at a time when scientists and investors alike are showing greater interest in, and enthusiasm for, the transformative impact that psychedelics may have on our approach to mental health and wellness. We would like to thank all of our shareholders for their ongoing support as we leverage our unique positioning in the market to grow the value of our company.”

The OTCQX Best Market is for established, investor-focused U.S. and international companies. To qualify for the OTCQX market, companies must meet high financial standards, follow best practice corporate governance, demonstrate compliance with U.S. securities laws, be current in their disclosure, and have a professional third-party sponsor introduction. Field Trip’s profile on the OTCQX website can be found here.

In addition to quotation of its shares on the OTCQX, Field Trip continues to explore options to enhance liquidity and access for global investors interested in investing in Field Trip, including potential up-listings or cross-listings to US or international exchanges and/or up-listing to senior exchanges in Canada, and also continues the process of securing Depository Trust Company (DTC) eligibility for its common shares. DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of US publicly traded companies. DTC eligibility is expected to simplify the process of trading and enhance liquidity of the Company’s common shares in the United States. 
 
About Field Trip Health Ltd.

Continue on your trip...

Field Trip is a global leader in the development and delivery of psychedelic therapies. With our Field Trip Discovery division leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics including psilocybin-producing fungi and our Field Trip Health division building centers for psychedelic therapies opening across North America and Europe along with the digital and technological tools that will enable massive scale, we help people, from those in treatment to those seeking accelerated personal growth, with a simple, evidence-based way to heal and heighten engagement with the world. 

Learn more at https://www.meetfieldtrip.com, https://www.fieldtriphealth.com  and  https://www.fieldtriphealth.nl

Follow us on Twitter and Instagram: @fieldtriphealth

To receive company updates about Field Trip and to be added to the email distribution list please sign up here.

For further information, contact Ronan Levy, Executive Chairman and a Director at Field Trip, at 1 (833) 833-1967. 

Cautionary Note Regarding Forward-Looking Information.
This release includes forward-looking information within the meaning of Canadian securities laws regarding Field Trip and its business, which may include, but are not limited to, statements with respect to the listing of the common shares of Field Trip on the Canadian Securities Exchange, and the timing of such events. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of Field Trip, and are based on assumptions and subject to risks and uncertainties. Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies, including risks regarding the COVID-19 epidemic, the medical clinic industry, market conditions, economic factors, management’s ability to manage and to operate the business and the equity markets generally. Although Field Trip has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Field Trip does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Neither the Canadian Securities Exchange, nor its Regulation Services Provider, nor the OTC Markets have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.

Media contacts:
Paige Tatulli
Autumn Communications
212-206-9780
paiget@autumncommunications.com / fieldtrip@autumncommunications.com

Investor contacts:
Elizabeth Barker
KCSA Strategic Communications
212-896-1203
ebarker@kcsa.com

SOURCE Field Trip Health Ltd.

Learn more about the psychedelics industry at Microdose.

Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Follow us on social